https://www.selleckchem.com/products/unc0379.html
development of COVID-19 vaccines is to reduce clinical phases II and III by using human challenge studies through eliberate infection of healthy volunteers with SARS-CoV-2 after administration of the candidate vaccine. Accelerating the development of a COVID-19 vaccine even for a few weeks or months would have a great beneficial impact on public health by saving many lives.In the original article there is an error in part a in the caption of Fig. 6. Following is the complete corrected caption.The aim of the study was to compare the tran
Curtir
Comentario
Compartilhar
